Comparing highly efficacious antimalarial drugs
2008
Comparing Antimalarial Drugs
publication
Author Information
Author(s): Colin Sutherland
Primary Institution: London School of Hygiene & Tropical Medicine
Hypothesis
How should phase III clinical trials for new antimalarial drugs be designed?
Conclusion
New antimalarial drugs must be tested against current effective treatments to ensure they are at least as effective.
Supporting Evidence
- Many African countries have implemented new malaria treatment policies based on artemisinin combination therapy.
- New combination therapies are needed to combat potential resistance to current treatments.
- Borrmann and colleagues recommend a non-inferiority study design for testing new therapies.
Takeaway
Scientists are trying to find better ways to test new malaria medicines to make sure they work as well as the ones we already have.
Methodology
Discussion of trial design and endpoints for phase III clinical trials of antimalarial drugs.
Limitations
The article discusses the challenges in standardizing trial designs and endpoints.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website